IBA Shares Climb 5.11% by Midday Monday, December 29
The stock of Belgian proton therapy specialist IBA marked a significant increase of 5.11% by midday on Monday, December 29, reaching 12.76 euros from 12.14 euros at last Friday's close. This rise follows a recent commercial announcement and reflects a renewed investor interest despite a limited exchanged share capital of 0.21%.
Seoul St. Mary's Hospital to Begin Patient Treatments by End of 2029
Seoul St. Mary's Hospital plans to start patient treatments by the end of 2029, contributing to the stable order book of the group, which remains at 1.3 billion euros. This new contract adds to a series of commercial successes recorded in the second half of 2025, particularly in Asia and the United States, where interest in proton therapy remains strong despite regulatory and pricing challenges. The Chaikin Money Flow (CMF) at 0.16 indicates a return of buying money flows after several months of selling pressures, signaling an improvement in investor confidence. The one-month volatility stands at 8.71%, a moderate level that could increase if the resistance at 12.54 euros is durably breached. The beta of 0.09 highlights the low correlation of the stock with market indices, allowing an independent trajectory driven by the company's own fundamentals and its prospects in cancer treatment.
